Related Experiment Video

Updated: Aug 9, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

[The interferon beta therapy after the first clinical episode of demyelination in multiple sclerosis]

T L Demina, N V Khachanova, M V Davydovskaia

    Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
    |April 13, 2006
    PubMed

    Insights

    Early inflammation and brain lesions in multiple sclerosis (MS) predict disease progression. Interferon beta treatment for clinically isolated syndrome (CIS) significantly reduces the risk of developing definite MS.

    Area of Science:

    • Neurology
    • Immunology
    • Radiology

    Background:

    • Multiple sclerosis (MS) treatment currently involves interferon beta preparations.
    • Emerging evidence indicates early axonal damage secondary to inflammation in MS.
    • Inflammatory activity in relapsing MS occurs before clinical episodes and during remission.

    Purpose of the Study:

    • To investigate the early pathological events in multiple sclerosis (MS).
    • To assess the risk factors for developing clinically definite MS (CDMS) from clinically isolated syndrome (CIS).
    • To evaluate the efficacy of interferon beta in preventing CDMS development in CIS patients.

    Main Methods:

    • Pathomorphological studies
    • Magnetic Resonance Imaging (MRI)
    • MR-spectroscopy
    • Immunohistochemical studies

    Main Results:

    • Axonal damage, secondary to inflammation, is present at the earliest stages of MS.
    • The number of brain lesions correlates with the onset of disability.
    • Interferon beta treatment in CIS patients significantly lowered the risk of progressing to CDMS.

    Conclusions:

    • Early pathological events and lesion load are critical predictors of MS progression.
    • Interferon beta therapy demonstrates a significant benefit in delaying or preventing the conversion to definite MS in high-risk individuals.

    More Related Videos

    Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin08:57

    Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

    Published on: March 26, 2015

    Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord10:44

    Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

    Published on: February 22, 2015

    Related Concept Videos

    Inhibitors of Viral Protein Synthesis01:30

    Inhibitors of Viral Protein Synthesis

    Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
    Multiple Sclerosis l: Introduction01:19

    Multiple Sclerosis l: Introduction

    Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...